Pulmatrix (NASDAQ:PULM) Stock Crosses Below Fifty Day Moving Average of $3.78

Pulmatrix, Inc. (NASDAQ:PULMGet Rating) shares crossed below its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $3.78 and traded as low as $3.70. Pulmatrix shares last traded at $3.74, with a volume of 21,064 shares trading hands.

Analysts Set New Price Targets

Separately, StockNews.com initiated coverage on Pulmatrix in a research note on Tuesday. They issued a “hold” rating on the stock.

Pulmatrix Price Performance

The firm has a 50 day moving average of $3.77 and a two-hundred day moving average of $4.01.

Pulmatrix (NASDAQ:PULMGet Rating) last released its quarterly earnings data on Thursday, November 10th. The biotechnology company reported ($1.45) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.51) by $0.06. The business had revenue of $1.87 million during the quarter, compared to analysts’ expectations of $1.16 million. Pulmatrix had a negative net margin of 387.03% and a negative return on equity of 46.03%. Equities analysts predict that Pulmatrix, Inc. will post -6.04 EPS for the current fiscal year.

Hedge Funds Weigh In On Pulmatrix

An institutional investor recently bought a new position in Pulmatrix stock. Citadel Advisors LLC purchased a new stake in Pulmatrix, Inc. (NASDAQ:PULMGet Rating) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 30,628 shares of the biotechnology company’s stock, valued at approximately $141,000. Citadel Advisors LLC owned 0.90% of Pulmatrix as of its most recent filing with the Securities and Exchange Commission. 15.69% of the stock is owned by hedge funds and other institutional investors.

Pulmatrix Company Profile

(Get Rating)

Pulmatrix, Inc is a clinical stage biotechnology company engaged in the discovery and development of novel inhaled therapeutic products for respiratory and other diseases. The firm focuses on the prevention and treatment of respiratory diseases and infections. It offers products based on its proprietary dry powder delivery technology, iSPERSE, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.

Read More

Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.